This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cel-Sci Settles Over South African Partner Flap

VIENNA, Va. ( TheStreet) -- Cel-Sci (CVM - Get Report) is paying $12 million in cash and stock to settle a lawsuit brought by a group of hedge funds investors allegedly cheated out of their investment when Cel-Sci later struck a drug licensing and discounted fund-raising deal with a mysterious South African partner.

Under terms of the settlement agreement, Cel-Sci will pay $3 million in cash and $9 million in stock -- both convertible notes and preferred shares -- to 13 hedge funds which participated in a 2006 financing deal, according to the company’s first-quarter regulatory filing.

Cel-Sci says it still disputes the allegations made by the hedge funds but chose to settle the lawsuit and pay the settlement as a way to move forward, according to its regulatory filing.

The central issue of dispute in this case centers on the identity of Byron Biopharma, a company chosen by Cel-Sci to market its experimental cancer drug Multikine in South Africa, if the drug is ever approved for sale.

In March 2009, Cel-Sci granted Byron Biopharma an exclusive license to market Multikine in South Africa. As part of this marketing partnership, Byron Biopharma was allowed to defer a license payment for Multikine -- which was later paid. Cel-Sci also sold deeply discounted stock to Byron that quickly turned into millions of dollars in paper profits due to an increase in the price of Cel-Sci shares.

The identity and business history of Byron Biopharma was not disclosed by Cel-Sci when the licensing agreement was announced in March 2009 and to this day, Cel-Sci executives have refused to answer questions about its South African partner.

Records show that Byron Biopharma was incorporated just days before it signed the South Africa Multikine licensing agreement in March 2009, but those records provided no information about Byron's permanent address, phone number or a list of executives and directors.

Cel-Sci claims that its deal with Byron Biopharma was and still is a legitimate drug marketing licensing deal. The 13 hedge funds alleged that Cel-Sci concocted Byron Biopharma to raise additional cash but purposefully avoid tripping anti-dilution provisions in their 2006 financing agreement with the company.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CVM $0.54 3.85%
AAPL $113.29 0.33%
FB $91.01 1.43%
GOOG $630.38 -1.13%
TSLA $248.48 2.26%

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs